Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer

• Published in: Gynecologic oncology Vol. 165; no. 1; pp. 14 - 22
• Main Authors: Vanderstichele, Adriaan, Loverix, Liselore, Busschaert, Pieter, Van Nieuwenhuysen, Els, Han, Sileny N., Concin, Nicole, Callewaert, Tiene, Olbrecht, Siel, Salihi, Rawand, Berteloot, Patrick, Neven, Patrick, Lambrechts, Diether, Van Gorp, Toon, Vergote, Ignace
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2022
• Subjects: Chemotherapy; Olaparib; Ovarian cancer; PARPi; Randomized; Recurrence; Recurrence; Chemotherapy; Olaparib; Randomized; PARPi; Ovarian cancer

Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT...